| Home | E-Submission | Sitemap | Contact Us |  

The Korean Journal of Pathology 2010;44(3): 234-242.
doi: https://doi.org/10.4132/KoreanJPathol.2010.44.3.234
Expression of Raf-1 Kinase Inhibitory Protein in Extrahepatic Bile Duct Carcinoma.
Hyun Soo Kim, Gou Young Kim, Sung Jig Lim, Youn Wha Kim
1Department of Pathology, Kyung Hee University Medical Center, Seoul, Korea. kimyw@khu.ac.kr
2East-West Neo Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.
BACKGROUND: Raf-1 kinase inhibitory protein (RKIP) recently has been identified as a metastasis suppressor in a variety of human carcinomas. The prognostic significance of RKIP expression in extrahepatic bile duct (EBD) carcinoma has not been studied. The aims of the current study were to evaluate RKIP expression and to determine the prognostic significance of RKIP expression in EBD carcinoma. METHODS: Immunohistochemical staining for RKIP was performed for 131 cases of EBD carcinoma. The associations of RKIP expression with clinicopathologic parameters and patient outcomes were examined. Multivariate logistic regression analysis was used to identify independent predictive parameters for lymphovascular invasion and nodal and distant metastases. RESULTS: Loss of RKIP expression was observed in 55.0% (72/131) of cases. EBD carcinoma had significantly lower RKIP immunoreactivity than normal EBD (p < 0.001). Loss of RKIP expression was significantly associated with lymphatic invasion (p = 0.030) and nodal metastasis (p = 0.036), but it was not found to be a significant prognostic predictor for overall, disease-free or distant metastasis-free survival. In addition, loss of RKIP expression was an independent predictor for lymphatic invasion (p = 0.027). CONCLUSIONS: These results suggest that RKIP may play a role in the suppression of lymphatic invasion and nodal metastasis in EBD carcinoma.
Key Words: Raf-1 kinase inhibitor protein; Immunohistochemistry; Bile duct neoplasms; Lymphatic metastasis